E I M M Reiss, M M van Haaren, J van Schooten, M A F Claireaux, P Maisonnasse, A Antanasijevic, J D Allen, I Bontjer, J L Torres, W-H Lee, G Ozorowski, N Vázquez Bernat, M Kaduk, Y Aldon, J A Burger, H Chawla, A Aartse, M Tolazzi, H Gao, P Mundsperger, M Crispin, D C Montefiori, G B Karlsson Hedestam, G Scarlatti, A B Ward, R Le Grand, R Shattock, N Dereuddre-Bosquet, R W Sanders, M J van Gils
The HIV-1 envelope glycoprotein (Env) trimer is the key target for vaccines aimed at inducing neutralizing antibodies (NAbs) against HIV-1. The clinical candidate immunogen ConM SOSIP.v7 is a stabilized native-like HIV-1 Env trimer based on an artificial consensus sequence of all HIV-1 isolates in group M. In preclinical studies ConM SOSIP.v7 trimers induced strong autologous NAb responses in non-human primates (NHPs). To fine-map these responses, we isolated monoclonal antibodies (mAbs) from six cynomolgus macaques that were immunized three times with ConM SOSIP...
November 25, 2022: NPJ Vaccines